Published in Cancer on February 01, 1995
Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med (2013) 2.20
Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol (1996) 1.45
Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer (2013) 1.39
Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol (2013) 1.22
The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer (2008) 1.12
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget (2013) 1.10
Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells. ACS Nano (2014) 0.97
Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer (2007) 0.96
Development of multidrug-resistance convertors: sense or nonsense? Invest New Drugs (2000) 0.93
Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? Oncotarget (2015) 0.91
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol (2013) 0.89
Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. Front Pharmacol (2013) 0.81
Treatment resistance mechanisms of malignant glioma tumor stem cells. Cancers (Basel) (2011) 0.81
Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma. Br J Cancer (1998) 0.75
Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med (1999) 11.44
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med (1993) 6.77
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med (1998) 5.74
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 4.73
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology (2002) 4.22
Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol (1992) 4.04
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol (1991) 3.01
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol (1989) 2.89
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol (1995) 2.89
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol (1995) 2.26
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs (1992) 2.22
Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax (1992) 2.11
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol (1998) 1.91
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res (1999) 1.80
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol (1993) 1.76
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol (2001) 1.76
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol (1994) 1.76
Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline. Chest (1991) 1.72
Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. Blood (1992) 1.69
A revised European-American classification of lymphoid neoplasms proposed by the International Lymphoma Study Group. A summary version. Am J Clin Pathol (1995) 1.67
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol (1991) 1.64
Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer (2001) 1.60
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol (1990) 1.57
Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest (1995) 1.56
P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood (1994) 1.55
Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res (1991) 1.50
Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood (1990) 1.50
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1994) 1.49
Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med (1988) 1.46
Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res (1993) 1.45
Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol (2012) 1.42
Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med (1996) 1.41
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol (1996) 1.41
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst (1991) 1.40
The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J Sci Am (1998) 1.40
Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1990) 1.39
Alternated versus syncopated CHOP-PVB: two studies for the treatment of non-Hodgkin's lymphoma by the Southwest Oncology Group. Cancer Invest (1991) 1.39
Intra-arterial thrombolysis (reteplase) and ReoPro for subacute thrombosis of the distal aorta accomplished by radial arterial access: the radial-kissing-thrombolytic technique. Catheter Cardiovasc Interv (2001) 1.39
Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group. Cancer (1997) 1.38
Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood (1994) 1.38
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials (2000) 1.33
Prognostic factors in multiple myeloma. Cancer (1975) 1.29
Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macrophages. N Engl J Med (1982) 1.27
Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res (1991) 1.25
Dose response effectiveness of propranolol for the treatment of angina pectoris. Circulation (1975) 1.22
Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol (1983) 1.21
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol (1995) 1.20
Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol (1993) 1.20
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol (1989) 1.19
A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg (1993) 1.19
Peripheral T-cell lymphoma: aggressive disease with heterogeneous immunotypes. Am J Clin Pathol (1985) 1.18
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol (1993) 1.16
Signet-ring cell lymphoma of T-cell origin. An immunocytochemical and ultrastructural study relating giant vacuole formation to cytoplasmic sequestration of surface membrane. Am J Surg Pathol (1985) 1.15
Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg (2000) 1.15
Primary renal artery stenting: characteristics and outcomes after 363 procedures. Am Heart J (2001) 1.14
The management of ovarian-cancer-caused bowel obstruction. Gynecol Oncol (1981) 1.14
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol (1993) 1.14
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood (1998) 1.13
Synchronous multicentric osteosarcoma: the case for metastases. Skeletal Radiol (1997) 1.11
Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res (2000) 1.11
Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol (2001) 1.11
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol (1999) 1.11
PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor. Immunopharmacology (1999) 1.10
Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett (1994) 1.10
Absence of clonal beta and gamma T-cell receptor gene rearrangements in a subset of peripheral T-cell lymphomas. Am J Pathol (1988) 1.09
HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest (1988) 1.08
Azathioprine-induced pure red blood cell aplasia. JAMA (1978) 1.08
NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol (2004) 1.08
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol (2001) 1.07
Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst (1989) 1.06
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol (2011) 1.06
The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood (2001) 1.05
Nodular lymphocyte predominance Hodgkin's disease. A distinct clinicopathological entity. Am J Surg Pathol (1994) 1.05
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol (1989) 1.04
A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. Cancer (1995) 1.04
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood (1996) 1.04
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control (2001) 1.04
Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol (1983) 1.04
Bronchogenic carcinoma presenting as spontaneous pneumothorax: case reports with review of literature. Cancer (1977) 1.03
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol (1999) 1.02
Residual intake and body weight gain: a new measure of efficiency in growing cattle. J Anim Sci (2011) 1.01
Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood (1990) 1.01
A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial. J Nutr Health Aging (2013) 1.00
Deep resequencing and association analysis of schizophrenia candidate genes. Mol Psychiatry (2012) 1.00
Long-term, low-level microwave irradiation of rats. Bioelectromagnetics (1992) 1.00
CALLA-positive myeloma: an aggressive subtype with poor survival. Blood (1985) 0.99
Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Ann Oncol (2005) 0.99
High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol (1999) 0.98
The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype. Blood (1988) 0.98
Characterization of four homologous L chain variable region genes that are related to 6B6.6 idiotype positive human rheumatoid factor L chains. J Immunol (1989) 0.98